NCT06788197View on ClinicalTrials.gov

A Study of SHR-A1811 and Fulvestrant, With or Without HS-10352, in Locally Advanced or Metastatic Breast Cancer Patients

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

March 31, 2025

Primary Completion Date

March 31, 2028

Study Completion Date

March 31, 2029

Conditions
Breast CancerLocally Advanced or Metastatic Breast Cancer
Interventions
DRUG

SHR-A1811+ Fulvestrant

SHR-A1811 is administered intravenously; fulvestrant is administered Intramuscular

DRUG

SHR-A1811+ Fulvestrant+HS-10352

SHR-A1811 is administered intravenously; fulvestrant is administered Intramuscular ； HS-10351 is administered orally

All Listed Sponsors
lead

Henan Cancer Hospital

OTHER_GOV